Ann: Half Yearly Report and Accounts, page-4

There isn't a trading halt. 

Plenty for all to digest.....

"The importance of the BIT225-009 trial results cannot be overestimated."

"The positive outcomes from this trial mean that Biotron is continuing discussions with key potential partners with compellingPhase 2 data in hand. Phase 2 is generally considered the best time to license technology to a major pharmaceuticalcompany as they have the expertise and resources necessary for late stage clinical development and regulatory approvalsin major markets such as the USA. This is not a fast process, nor is there a guarantee of a successful commercial outcome."

If you are after a quick buck go elsewhere. Long term holders sit tight.